A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

NCT ID: NCT00000889

Last Updated: 2021-10-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1997-10-31
• Study Completion Date: 1999-12-31

Brief Summary

To demonstrate the safety and tolerability of subcutaneously administered interleukin-2 (IL-2) plus antiretrovirals in patients with HIV infection and CD4 counts of 350 cells/mm3 or more. To demonstrate the immunological efficacy of subcutaneous IL-2 therapy plus antiretroviral therapy relative to antiretroviral therapy alone.

IL-2, given through injection under the skin, in combination with anti-HIV therapy can increase CD4 cell counts. This study examines 3 doses of IL-2 in order to determine the safest and most effective dose to use.

Detailed Description

Interleukin-2 administered subcutaneously, in combination with antiretrovirals, results in increases in CD4+ cell count that might impact upon HIV disease progression. A Phase III trial involving large numbers of HIV-positive patients is the next step in the development process. To develop appropriate clinical experience with the combination, this Phase II trial will allow administration of IL-2 plus antiretroviral therapy to a small number of patients in sites being considered for the Phase III trial.

Patients are randomized to control therapy with antiretrovirals alone (36 patients) or antiretrovirals plus IL-2 given subcutaneously every 12 hours for 5 days every 8 weeks. Three doses of IL-2 are studied, with 12 patients evaluated at each dose.

If at least 9 of the first 12 patients complete the 5-day dosing period without dose-limiting toxicities, the next 12 patients randomized are treated with the next higher dose; if this dose is tolerated, the last 12 patients randomized receive the highest study dose. Patients enrolled at the first two doses of IL-2 who complete three courses have their dose escalated to a maximum of the highest dose.

Conditions

HIV Infections

Keywords

Interleukin-2; CD4 Lymphocyte Count; Anti-HIV Agents

Study Design

• Primary Study Purpose: TREATMENT

Interventions

Aldesleukin

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

You may be eligible for this study if you:

• Are HIV-positive.
• Have a CD4 cell count greater than or equal to 300 cells/mm3.
• Are at least 18.
• Have been on antiretroviral therapy for at least 7 days prior to study entry.

Exclusion Criteria

You will not be eligible for this study if you:

• Abuse alcohol or drugs, or have any serious psychiatric or medical illnesses that would affect your safety or ability to complete the study.
• Have a history of cancer (other than Kaposi's sarcoma), an AIDS-defining illness, a central nervous system (CNS) abnormality, or an autoimmune/inflammatory disease.
• Are pregnant or breast-feeding.
• Have ever received IL-2.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

M Losso

Role: STUDY_CHAIR

Locations

Hospital de Clinicas 'Jose de San Martin' C601-040 CRS

Ciudad de Buenos Aires, Buenos Aires, Argentina

Hospital F.J. Muniz C601-050 CRS

Ciudad de Buenos Aires, Buenos Aires, Argentina

Hospital General de Agudos J.M. Ramos Mejia CPCRA CRS

Ciudad de Buenos Aires, Buenos Aires, Argentina

Hospital Italiano de Buenos Aires C601-020 CRS

Ciudad de Buenos Aires, Buenos Aires, Argentina

Countries

Argentina

Other Identifiers

10467

Identifier Type: REGISTRY

Identifier Source: secondary_id

SQ 1 ARG

Identifier Type: -

Identifier Source: secondary_id

SQIL-2 Argentina

Identifier Type: -

Identifier Source: secondary_id

IRP 021A

Identifier Type: -

Identifier Source: org_study_id